Published on 10 Apr 2024 on Zacks via Yahoo Finance
Fresenius Medical Care AG & Co. KGaA FMS is well-poised for growth on the back of a broad range of dialysis products and services and a solid global foothold. However, stiff competition remains a concern.
Shares of this Zacks Rank #3 (Hold) company have lost 7.7% year to date against the industry’s growth of 7%. The S&P 500 Index has increased 9.2% in the same time frame.
The company, with a market capitalization of $11.09 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 13.6% over the next five years. FMS’ earnings beat estimates in three of the trailing four quarters and missed the same once, delivering an average surprise of 25.81%.